Patents & Intellectual Property Rights

The concept of the economic moat

Warren Buffett coined the term 'economic moat' in the 1990s as a metaphor for the structural advantages that protect a company's profits from competitors. Just as a medieval castle had a moat filled with water to prevent enemies from storming the castle, some companies have moats that stop competitors from eroding their profitability. Buffett's point is subtle but critical: it is not enough for a company to be profitable today — there must be a reason the profitability will persist. Without a moat, competition will drive the return down to the industry average, no matter how good the company is right now. The moat is what separates a 'good company' from a 'good business'. A good company can have 20% ROE today; a good business has 20% ROE in 10 years because no one can copy it. Patents & intellectual property rights are the most concrete and measurable form of moat — it is written into law, time-limited, and geographically defined. That is why it is V13 — the first variable in the Moat category.

💡 INSIGHT

Buffett's test: 'If a billionaire with unlimited capital started a competitor tomorrow, could it erode the company's profits?'. If the answer is no — the company has a moat. Patents make the answer no for 20 years. Brands make the answer no for decades. Networks make the answer no indefinitely.

Five types of moat — where IP fits in

📖 DEFINITION

Why the IP moat is the most measurable

The life cycle of a patent — four phases

A patent goes through four economic phases. Phase 1: application — the company submits the application, the patent is under examination (1-5 years), protection is uncertain, costs are high (application fees, lawyers, translations into several languages). Phase 2: grant — the patent authority grants the patent, protection begins, but the company must pay annual renewal fees to keep it alive. Phase 3: commercial exploitation — the company launches the protected product, or licenses out the patent, or uses it defensively (against lawsuits). This is where the revenue is generated. Phase 4: expiry — 20 years after the application the patent expires and the product becomes 'generic' — competitors can copy freely. AstraZeneca's Omeprazol illustrates: patent applied for 1979, granted 1985, launched as Losec 1988-1998 (peak sales 6,2 billion USD in 1996), patent expired 2002-2014 (varying by geography), sales fell to 10% of peak in five years. For the analyst this is cyclical: a pharmaceutical company MUST constantly develop new patents because old ones expire. This is called the 'pipeline' and is the most important forward-looking metric for pharmaceutical companies.

✓ TIP

Read the 'R&D pipeline' in the pharmaceutical company's investor presentation. Phase 1 (pre-clinical), Phase 2 (clinical), Phase 3 (pivotal). A patent with Phase 3 approval is worth 100x a Phase 1 patent.

Patent quality — not quantity decides

A common beginner's mistake is to count patents and conclude 'more patents = stronger moat'. This is wrong. Quality weighs more than quantity. Four quality dimensions: First — validity: a granted patent is not guaranteed valid; 30-50% of patents challenged in court are invalidated. Look for 'upheld in litigation' as a quality indicator. Second — breadth: a 'blocking patent' covering an entire product is worth 1000x a 'narrow patent' covering a specific detail. Breadth is measured in 'claims' — the number of patent claims. Third — geographic coverage: a patent in Sweden only protects in Sweden. A patent in the USA, EU, Japan, China, and India protects 80% of the world market. The cost is 5-10x higher but the value is 50x. Fourth — remaining lifetime: a patent expiring in 2 years is worth 5% of one with 15 years left. Discount rate: 20% per year. A concrete example: Ericsson has 60 000+ patents granted, but the 5G standard patents (SEP — Standard Essential Patents) are the valuable ones. These are 3-5% of the portfolio but generate 90% of license revenue. Quality, not quantity.

⚠️ WARNING

Companies that boast of 'over 1000 patents' without reporting quality, geographic coverage, or commercial value are often 'IP inflation'. Look for license revenue (royalty income) — the only real proof that the patents are valuable.

Commercialization — three paths to revenue

A patent can generate revenue in three ways. Path 1: product protection — the company sells a product protected by the patent; competitors cannot sell the same product. This is the most common and most valuable form (AstraZeneca, Atlas Copco). The revenue is product sales, not a license fee. Path 2: licensing OUT — the company owns the patent but lets others pay to use it. Ericsson has 25+ billion SEK annually in license revenue from 4G/5G patents; Qualcomm has 6 billion USD annually. This is high-quality revenue — 90%+ margin, recurring, scalable. Path 3: defensive protection — the company does not use the patent commercially but holds it to prevent competitors from suing them. This is common in the tech industry where 'patent wars' are common (Apple vs Samsung 2011-2018). The value is avoided costs, not revenue. For the analyst, path 2 is most interesting — license revenue is high-margin and can grow exponentially. A company that has 10% of revenue from licensing but 30% of profit is a 'hidden champion'. Read notes to the accounts on 'royalty income' or 'licensing revenue' in the annual report.

⚡ KEY INSIGHTS Patent cycle: application → grant → commercialization → expiry (20 years) Quality > quantity — validity, breadth, geography, and lifetime decide Three commercialization paths: product protection, licensing OUT, defensive License revenue is high-margin (90%+) — Ericsson 25+ MSEK annually from 5G licenses 3